A prospective observational study of immune-checkpoint inhibitor (Nivolumab) treatment in patients with non-small cell lung cancer
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000021600
- Lead Sponsor
- Kitasato University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Monitoring a progress of Nivolumab treatment for non-small cell lung cancer patients
- Secondary Outcome Measures
Name Time Method